← All stocks

Evommune, Inc.

EVMN No buying or selling

CIK 0002044725 #3118 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

$0.00

$0.00 against sales at will

By person

13 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

LSP 7 Cooperative UA

Director

—

10,217,946

$135.49M

+107.3%

Verduyn-van Weegen Felice Isabel

Director

—

5,288,313

$70.12M

—

RA CAPITAL MANAGEMENT, L.P. entity

Director

—

2,710,293

$35.94M

—

Pena Luis C.

President & CEO

—

630,458

$8.36M

−4.3%

Pivotal bioVenture Partners Fund I, L.P. entity

Director

—

294,502

$3.91M

—

Bauer Eugene

Chief Medical Officer

—

270,818

$3.59M

+9.9%

Drew Janice Suzann

Chief of Dev. Operations

—

67,794

$898.95K

−4.9%

Moss Gregory S.

Chief Business & Legal Officer

—

64,010

$848.77K

−14.0%

Carver Kyle

Chief Financial Officer

—

60,335

$800.04K

−16.9%

Patel Jeegar Pravinkumar

Chief Scientific Officer

—

46,403

$615.30K

−13.9%

Cohen David E

Director

—

17,609

$233.50K

0.0%

KIRSCH ARTHUR S

Director

—

10,000

$132.60K

—

Hopfner Robert Lorne

Director

—

4,026

$53.38K

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 0

History held since 7 Nov 2025